Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hypercoagulability and tissue factor gene upregulation in hematologic malignancies.
|
18645927 |
2008 |
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases.
|
15213854 |
2004 |
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cancer histology influences the risk of venous thromboembolism and tissue factor (TF) is the key molecule in cancer-induced hypercoagulability.
|
21917301 |
2012 |
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings suggest that TF-specific PCA of plasma MPs contributes to intravascular coagulation activation in patients with early-stage prostate cancer and may represent a potential link between hypercoagulability, inflammation, and disease progression.
|
19492160 |
2009 |
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Consequently, expression of tissue factor, urokinase receptor, and PAI-1 mRNA and PAI-1 protein secretion induced by busulfan were significantly reduced by the activin A/TGF-β1 inhibitor SB 431542 in ECV304 and primary endothelial cells.Conclusions This is the first report that directly relates busulfan exposure to antifibrinolytic activity by PAI-1 and hypercoagulation possibly mediated by members of the TGF-β1 family.
|
22286157 |
2012 |
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of miR-19b and miR-20a observed in patients with SLE and APS could contribute to increased TF expression and thus provoke the hypercoagulable state characteristic of these patients.
|
21794077 |
2011 |
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to a time-of-day effect present within TF, peaking at 0830, caution should be applied when prescribing short-duration high-intensity exercise bout within the morning in populations predisposed to hypercoagulability.
|
29320303 |
2018 |
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging evidence suggests that indoxyl sulfate is implicated via novel mechanisms, including progenitor cell-related neovascularization and tissue factor-related hypercoagulability.
|
28067862 |
2017 |
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evidence suggests that cancer itself is associated with a state of hypercoagulability, driven in part by the release of procoagulant factors, such as tissue factor, from malignant tissue as well as by inflammation-driven activation of endothelial cells, platelets, and leukocytes.
|
27882374 |
2017 |
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HFP induces plasma hypercoagulability that is likely related to increased tissue factor and phosphatidylserine expression originating from cell-derived MP.
|
27941590 |
2017 |
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IFN and CRP further increase TF levels that may contribute to the hypercoagulable state in coronary disease.
|
16409458 |
2006 |
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion we found a hypercoagulable state in patients with haematological malignancy that did not seem to be initiated by TF.
|
18521506 |
2008 |
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Indeed, systemic hypercoagulability in patients with cancer and TF overexpression by cancer cells are both closely associated with tumor progression, but their causes have been elusive.
|
15494427 |
2005 |
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It is hoped that because we currently have such simple and clinically useful global tests of hypocoagulability as the prothrombin time and activated partial thromboplastin time, it may soon become possible to measure multifactorial thrombophilia without resorting to the multiplicity of tests now necessary.
|
15706469 |
2005 |
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Oncogenic events in cancer cells (e.g., expression of mutant K- ras, EGFR, PTEN or p53) lead to an increase in TF levels and activity, and thereby promote tumor aggressiveness, angiogenesis, and hypercoagulability.
|
16479463 |
2006 |
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
PAD4 and RAGE knockout mice, deficient in NET formation, were used to study the role of NETs in platelet aggregation, release of tissue factor and hypercoagulability.
|
29929491 |
2018 |
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pancreatic cancer is characterised by high tumoural expression of tissue factor, activation of leukocytes with the release of neutrophil extracellular traps, the dissemination of tumour-derived microvesicles that promote hypercoagulability and increased platelet activation.
|
31327867 |
2019 |
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
PH is not associated with splenectomy status but correlated with NO depletion, TF-independent hypercoagulability and endothelial perturbation.
|
30584959 |
2019 |
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Platelet activation has been associated with an epithelial to mesenchymal transition (EMT), while Tissue Factor (TF) protein expression by cancer cells has been shown to correlate with hypercoagulable state and metastasis.
|
25886038 |
2015 |
Thrombophilia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently published guidelines on thrombophilia testing recommend assays for protein C, protein S and antithrombin; a modified activated protein C resistance test (with factor V-deficient plasma); polymerase chain reaction for prothrombin G20201A, together with prothrombin time, activated partial thromboplastin time, thrombin clotting time and assays to detect antiphospholipid antibodies.
|
12680634 |
2003 |
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
She also had shortened activated partial thromboplastin time indicating a hypercoagulable state and resulting in pulmonary embolism.
|
31362300 |
2019 |
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The higher availability of surface TF antigen on MNCs from HRs and TF-containing microparticles might make these individuals more susceptible to hypercoagulation.
|
15860742 |
2005 |
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings strongly support the hypothesis that antibodies to PF4 developed in HIT trigger the production of tissue factor by monocytes, and this effect could account in vivo for hypercoagulability and thrombotic complications in affected patients.
|
11342462 |
2001 |
Thrombophilia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest a significant role of moDCs and the complement system through TF expression in a hypercoagulable state under inflammatory conditions and demonstrate the suppressive effects of C1 inhibitor on moDC-associated hypercoagulation.
|
29860607 |
2018 |
Thrombophilia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to investigate whether circulating TF-positive MPs contributed to the hypercoagulable state in patients with IMN.
|
30429407 |
2019 |